Streetbeat News

Revenues

IART

Analysts have provided diverse opinions on Integra Lifesciences (NASDAQ:IART) with recent ratings ranging from bullish to bearish. Over the past quarter, there have been 3 somewhat bullish and 2 indifferent ratings. The average 12-month price target for IART is $48.6, reflecting a 9.21% increase from the previous target of $44.50. Key analysts from JMP Securities, Truist Securities, and Wells Fargo have adjusted their ratings and price targets, indicating a nuanced view of the company's financial health and market position. Integra Lifesciences, a medical equipment company, faces challenges in revenue growth and debt management but excels in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 8:01 pm

TJX

In the last three months, TJX Companies (NYSE:TJX) received diverse analyst ratings, with a shift towards a more positive outlook. The average 12-month price target for TJX has increased to $106.4, up 6.4% from $100. TJX's financial performance shows strong growth, with a revenue increase of 9.02% as of October 31, 2023, and outperforming industry averages in net margin, ROE, and ROA. The company's debt management is also highlighted as sound, with a debt-to-equity ratio of 1.83.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 8:00 pm

EFX

Equifax (NYSE:EFX) received mixed analyst ratings in the last quarter with 13 analysts offering views ranging from bullish to bearish. The average 12-month price target is $279.08, marking a 34.95% increase from the previous target of $206.80. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics and Equifax's performance. Equifax, a leading credit bureau, has shown notable revenue growth and a strong market presence but faces challenges in debt management and ROE.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 8:00 pm

EA

Electronic Arts Inc (NASDAQ:EA) has canceled the development of a Star Wars FPS game featuring a Mandalorian protagonist and laid off about 670 employees, 5% of its workforce, as part of a restructuring effort. The company is shifting focus towards its own IPs and key franchises, including the Star Wars: Jedi, Iron Man, Black Panther, and others. Despite these changes, EA reported positive financial results but expects to incur costs related to the layoffs.

Portfolio Pulse from Franca Quarneti

February 29, 2024 | 7:24 pm

MEG

Montrose Environmental Group's shares surged following the announcement of Q4 earnings surpassing expectations and the issuance of FY24 revenue guidance that exceeded consensus estimates.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 7:03 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) has received mixed analyst ratings over the last quarter, with a shift towards a more cautious outlook. The average 12-month price target has been adjusted to $55.25, down from $69.00, indicating a 19.93% decrease. Analysts from firms like Cantor Fitzgerald, JMP Securities, Raymond James, and HC Wainwright & Co. have provided updates, with some maintaining their ratings and others lowering their price targets. Mirum Pharmaceuticals, a biopharmaceutical company, focuses on therapies for rare diseases and has shown significant revenue growth and a strong market presence, despite challenges in debt management and return on equity.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:02 pm

DCGO

Four analysts have recently shared mixed evaluations of DocGo (NASDAQ:DCGO), with a shift towards more bullish ratings in the last 30 days. The average 12-month price target for DCGO has been adjusted to $10.5, down from $12.50, indicating a 16.0% decrease. DocGo's financial performance shows strong growth and profitability, with significant revenue growth and above-average net margin, ROE, and ROA. The company's low debt-to-equity ratio suggests prudent financial management.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:01 pm

STEM

Stem (NYSE:STEM) has received mixed analyst ratings over the past three months, with a shift towards a more cautious outlook. The average 12-month price target for STEM has been lowered to $4.05, indicating a 26.36% decrease from the previous target of $5.50. Analysts from firms including Susquehanna, Piper Sandler, BMO Capital, Goldman Sachs, and Morgan Stanley have all adjusted their ratings and price targets downwards, reflecting concerns over market conditions and company performance. Despite this, Stem's financials show a positive revenue trend with a growth rate of 34.41% as of September 30, 2023, but challenges in net margin, ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:00 pm

UNH

UnitedHealth Group (NYSE:UNH) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target for UNH is $583.22, slightly up from the previous $583.00. Analysts from firms like RBC Capital, Stephens & Co., Cantor Fitzgerald, Oppenheimer, Piper Sandler, and HSBC have maintained or adjusted their ratings and price targets, reflecting their views on the company's market position and financial health. UnitedHealth Group, a leading private health insurer, has shown strong financial performance with notable revenue growth, net margin, ROE, and ROA, despite a higher debt-to-equity ratio compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 7:00 pm

AGFY

Agrify Corporation's stock price increased following the announcement of a $3.4 million sales order from HarvestWorks Farm.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 6:41 pm